All companies
Hugel Inc. logo

What smart money is saying about Hugel Inc.South Korea flag

145020.KQ · Healthcare · Biotechnology · Market cap $1.89B

2 funds in our archive have pitched Hugel Inc. — most recently Polen Emerging Markets Growth in December 2025.

Company profile

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.

Fund coverage · 2 theses

  • Polen Emerging Markets Growth
    December 2025

    Hugel Inc. is a South Korean leader in botulinum toxin and fillers with attractive valuation, cost-efficient production, and anticipated U.S. approvals to drive international growth.

    Read the full thesis
  • Polen Emerging Markets Growth
    September 2025

    Hugel is the South Korean leader in medical aesthetics, specializing in botulinum toxin and hyaluronic acid fillers, with an attractive investment case due to its valuation, efficient production, and anticipated international expansion.

    Read the full thesis

Read every full thesis on Hugel Inc.

Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans